Apsynora has been selected to join the Estonian DeepTech Accelerator, marking an important step forward in the development of our therapeutic concept and future growth.
milestone
Apsynora Therapeutics Selected for the Estonian DeepTech Accelerator
09 June 2026
milestone
Apsynora has been selected among 11 teams from 24 applicants to join the Estonian DeepTech Accelerator, supporting the development of our business model, funding strategy, and growth plans. The programme will provide expert guidance, mentoring, and workshops focused on strengthening our team and validating the solution–problem fit. We are excited to take the next step in developing our therapeutic concept and building the foundation for future clinical development and growth.
About Apsynora Therapeutics
Apsynora Therapeutics is a clinical-stage biopharmaceutical company focused on advancing innovative therapeutic solutions. Our lead programme, HT-101, is being developed to reduce or relieve gastrointestinal side effects associated with GLP-1 receptor agonist therapies. By combining clinical development with a science-driven approach, Apsynora Therapeutics aims to improve treatment tolerability and support patients in benefiting from important therapeutic advances.